WC
PBYI icon

Wexford Capital’s Puma Biotechnology PBYI Stock Holding History

Wexford Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-57,331
Closed -$3.84M – 292
2016
Q3 		$3.84M Buy
+57,331
New +$2.9M 0.63% 51
2014
Q4 		– Sell
-18,495
Closed -$4.41M – 93
2014
Q3 		$4.41M Buy
+18,495
New +$3.8M 0.41% 42
2014
Q2 		– Sell
-36,034
Closed -$3.75M – 155
2014
Q1 		$3.75M Buy
+36,034
New +$4.24M 0.28% 62

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wexford Capital's PBYI Position: Q4 2016 in Review

Wexford Capital sold out of Puma Biotechnology (PBYI) in Q4 2016, closing a stake of 57,331 shares — an estimated $3.84M sold.

Wexford Capital first reported a position in PBYI in Q1 2014 and held it in 3 quarters. The position peaked at $4.41M in Q3 2014. 128 funds tracked by Wall St. Rank hold PBYI as of Q4 2016.

  • Wexford Capital reported no remaining Puma Biotechnology position as of Q4 2016 after selling out during the quarter.
  • Wexford Capital sold 57,331 Puma Biotechnology shares in Q4 2016, an estimated $3.84M.
  • Wexford Capital first reported a position in Puma Biotechnology in Q1 2014 and held it in 3 quarters.
  • Wexford Capital's Puma Biotechnology position peaked at $4.41M in Q3 2014.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2016.

Based on Wexford Capital's 13F filing for Q4 2016, filed 14 Feb 2017.